A new, phenoxo-bridged Cu II dinuclear complex Cu 2 [(L) 2 (DMF) 2 ] (1) has been obtained by employing the coumarin-assisted tridentate precursor, H 2 L, [benzoic acid(7-hydroxy-4-methyl-2-oxo-2H-chromen-8ylmethylene)-hydrazide]. Complex 1 has been systematically characterized by FTIR, UV-Vis, fluorescence and EPR spectrometry. The single crystal X-ray diffraction analysis of 1 shows that the geometry around each copper ion is square pyramidal, comprising two enolato oxygen atoms belonging to different ligands (which assemble the dimer bridging the two metal centers), one imine-N and one phenolic-O atoms of the Schiff base and one oxygen atom from the DMF molecule. The temperature dependent magnetic interpretation agrees with the existence of weak ferromagnetic interactions between the bridging dinuclear Cu(II) ions. Both the ligand and complex 1 exhibit anti-mycobacterial activity and considerable efficacy towards M. tuberculosis H37Rv ATCC 27294 and M. tuberculosis H37Ra ATCC 25177 strains. The cytotoxicity study on human adenocarcinoma cell lines (MCF7) suggests that the ligand and complex 1 have potential anticancer properties. Molecular docking of H 2 L with the enoyl acyl carrier protein reductase of M. tuberculosis H37R v (PDB ID: 4U0K) is examined and the best docked pose of H 2 L shows one hydrogen bond with Thr196 (1.99 Å).

No abstract

No abstract

No abstract